Biotechnology

Emerging Growth Research Issues Company-Sponsored Research Flash Report on OSR Health, Inc.

August 27, 2026 5:00 PM

Emerging Growth Research, LLC ("Emerging Growth Research" or "EGR") today announced the release of its company-sponsored research flash report on OSR Health, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing oral immunotherapies for cancer and age-related disease, non-invasive glucose monitoring technology, and fourth-party logistics (4PL) operations. This release is being issued as an updated version of EGR's previously...

Read more

enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference

August 27, 2026 9:01 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company") today announced that Robert Berman, Chief Executive Officer of enVVeno Medical, participated in the Virtual Investor "Why Now" on-demand conference. For the event, Mr. Berman highlighted the Company's investment opportunity, including the significant unmet need for effective treatment options for patients with severe Deep Venous Insufficiency (DVI) and the substantial...

Read more

RMTG's Cellgenic Division Introduces MUSE Cell Product Line Across Four International Regions

August 27, 2026 7:01 AM

Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced the introduction, through its Cellgenic division, of a multilineage-differentiating stress-enduring (MUSE) cell product line for selected international markets - including Latin America, the Middle East, Europe, and Southeast Asia - subject to...

Read more

Biovica Expands Pharma Services Business with New Master Services Agreement

August 27, 2026 6:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a company specializing in blood-based cancer monitoring, today announces that it has entered into a Master Services Agreement (MSA) with an operating subsidiary of a U.S.-based biotechnology company developing next-generation precision medicines for cancer. The agreement establishes a framework for the use of Biovica's DiviTum® TKa testing services in the customer's oncology...

Read more

Faro Raises $37.3M Series B to Scale Agentic AI Across Clinical Development

August 26, 2026 9:35 AM

Faro AI, Inc. today announced it has raised $37.3 million in Series B financing. The round was co-led by Merck Global Health Innovation Fund and S32, with participation from all existing investors, including General Catalyst, Northpond Ventures, Polaris Partners, PTX Capital, and Zetta, and new investors, including Ankona Capital. Faro AI logo / Source: Faro AI (EZ Newswire) The financing will fund Faro's next stage of growth as pharmaceutical...

Read more

RMTG Acquires RMTG.com Domain and Launches New Investor-Focused Website, Advancing Shareholder Engagement

August 26, 2026 7:02 AM

Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced that it has acquired the domain name RMTG.com, and launched a new investor-focused corporate website at that address. The site is intended to serve as a central, easily accessible destination for the Company's investor communications, corporate...

Read more

Bulletin from the Extraordinary General Meeting in Alligator Bioscience AB

August 26, 2026 5:50 AM

Alligator Bioscience (STO:ATORX) - Today, on 26 August 2026, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follows below. Resolution on (A) amendment of the Articles of Association; (B) decrease of the share capital to cover loss; and (C) decrease of the share capital for allocation to unrestricted shareholders' equity The meeting resolved to amend § 4 of the Articles of Association so...

Read more

Vicore Pharma to Present at The Pareto Securities 17th Annual Healthcare Conference

August 26, 2026 2:20 AM

Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(Nasdaq US:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the Pareto Securities 17th Annual Healthcare Conference in Stockholm. Location: Hotel At Six, Stockholm, Sweden Format: Presentation and 1×1 meetings Presentation Date and Time:...

Read more

Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers

August 25, 2026 7:00 AM

For Germantown, MD-based Precigen Inc. (NASDAQ:PGEN), the second quarter marked a commercial inflection. PAPZIMEOS (zopapogene imadenovec-drba) generated $53.1 million in net product revenue-more than double the prior quarter-and helped the company achieve quarterly profitability. Validated Platform President and CEO Helen Sabzevari, PhD, framed the quarter as platform validation. "PAPZIMEOS demonstrates the AdenoVerse platform's ability to...

Read more

New Publication Broadens the Potential of DiviTum TKa in Immuno-Oncology

August 25, 2026 3:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a company specializing in blood-based cancer monitoring, today announced that new results involving DiviTum® TKa have been published in the peer-reviewed journal Clinical Cancer Research. The study evaluated DiviTum TKa in patients with metastatic melanoma receiving different sequences of immunotherapy and targeted therapy. These patients can receive both types of treatment,...

Read more

FluoGuide A/S Publishes Interim Report for Q2 2026

August 25, 2026 1:30 AM

Fluoguide A/S (STO:FLUO) ("FluoGuide" or the "Company") today releases its results for the period 1 January 2026 - 30 June 2026. The Q2 report is available as attached document to this press release and on FluoGuide's website. "The second quarter marked another step forward in the clinical trials with FG001. In our Phase 2 clinical trial in oral head and neck cancer (CT-005) we enrolled the last patient in the first part of the trial and...

Read more

Vibrant Wellness Brings the Most Comprehensive Gut Health Test to New York

August 25, 2026 12:00 AM

Vibrant Wellness, a specialty laboratory company, announced New York availability for Gut Zoomer, bringing the most comprehensive gut health assessment to New York and marking a significant expansion of access to advanced microbiome testing. New York maintains rigorous state-specific requirements for clinical laboratories and laboratory-developed tests. Meeting the requirements set forth by New York's Clinical Laboratory Evaluation Program...

Read more

RMTG's Cellgenic Division Launches Natural Killer (NK) Cell Product Line for International Markets

August 24, 2026 7:01 AM

Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, announces the launch, through its Cellgenic division, of a Natural Killer (NK) cell product line for permitted markets outside the United States, with an initial commercial focus on Latin America and Southeast Asia. NK cells are a class of cytotoxic lymphocytes...

Read more

Vicore Pharma to Present at the European Respiratory Society Congress 2026

August 24, 2026 2:15 AM

Vicore Pharma Holding AB (NASDAQ Stockholm:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists, today announced that the company will participate in the European Respiratory Society (ERS) Congress 2026, taking place in Barcelona, Spain and online September 5-9, 2026. Vicore will present new data on the design and baseline characteristics of...

Read more

OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission 

August 21, 2026 11:45 AM

OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from its Chief Executive Officer to shareholders. To OSR Health Shareholders: I am aware that many of you are watching closely to see what comes next. I want to address some of your concerns directly and with specificity. OSR Health's stock is showing resilience this morning after a difficult session yesterday. In our opinion, that resilience reflects something real: the...

Read more

eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today

August 20, 2026 4:10 PM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - will host an investor webinar today at 5:00 PM Eastern Time to discuss results for the second quarter ended June 30, 2026, and provide an update on recent business developments. Michael Heltzen, CEO of eXoZymes, states, "We have taken a molecule from concept to pilot validation...

Read more

BioInvent Announces Publication of Preclinical Manuscript on BI-1808 and BI-1910 in Cancer Research

August 20, 2026 8:15 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that a preclinical manuscript characterizing the mechanism of action, broad antitumor efficacy, and ability to elicit antitumor immunity of BI-1808 and BI-1910 has been published in Cancer Research, a peer-reviewed journal of the American Association for Cancer Research. The publication is entitled...

Read more

Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement

August 20, 2026 8:00 AM

Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE), a clinical-stage biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, is pleased to announce the closing of its previously announced non-brokered private placement offering of 24,705,880 common shares in the capital of the Company ("Common Shares") at a price of $0.085 per Common Share, for aggregate gross...

Read more

RMTG More Than Quadruples Revenue and Gross Profit in Q2 2026 Versus Q2 2025, With Operating Income Surpassing $560,000

August 20, 2026 7:01 AM

Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced its financial results for the second quarter of 2026 (Q2 2026), for the period ended June 30, 2026,as reported in the Company's Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on August 19, 2026. The results...

Read more

Invitation to Alligator Bioscience's Earnings Call on 26 August 2026

August 20, 2026 3:00 AM

Alligator Bioscience (STO:ATORX), a biotechnology company whose principal asset is a financial interest in the HER2-targeting antibody programme HLX22, will publish its interim report for April - June 2026 on Wednesday, 26 August 2026, at 8:00 a.m. CEST. On the same day, Alligator will host a webinar and conference call for investors, analysts and media at 3:00 p.m. CEST / 9:00 a.m. EDT, where CEO Søren Bregenholt and CFO Johan Giléus will...

Read more